Article Text

Download PDFPDF
Is nucleic acid amplification point-of-care testing for chlamydia and gonorrhoea cost-effective?
  1. Alec Miners
  1. Correspondence to Dr Alec Miners, Health Services Research and Policy, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SY, UK; alec.miners{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Chlamydia and gonorrhoea continue to be the most treatable bacterial infections in the UK, and they remain a considerable public health concern. The historical concern with point-of-care (POC) testing for chlamydia and gonorrhoea has been the reliance on tests with unacceptable levels of diagnostic accuracy. In this addition of STI, Turner and colleagues present an assessment of the possible costs and benefits of a ‘novel’ POC nucleic acid amplification test (NAAT). There is considerable appeal and logic in rapid and accurate diagnostic tests for these infections. When compared with laboratory-based tests, POC NAAT testing could reduce the delay in receiving test results to a matter of hours rather than days, meaning individuals are more likely to receive timely and appropriate treatment. Not only would …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer.

Linked Articles